Cancer Stem Cell Treatments

ADVANCED CANCER

Candidates: Patients with advanced cancer that have had previous chemotherapy and/or radiation and/or surgery that has failed and the patient has had recurrence or metastasis. Age and severity of the current condition do not limit the availability of this treatment.

Ideally we would request a detailed summary of the patient’s records including biopsy reports, most recent laboratory findings, x-ray results and list of all previous treatments; an immunological profile including T and B lymphocytes, NK cells, T cytotoxic cells and T regulatory (suppressor) cells. The attack is focused on residual cancer stem cells that have resisted chemotherapy or radiation effects.

Patients undergoing treatment will receive the following approach:

Infusion autologous stem cells and CD33+ and CD134+ cells i.v. over a ten minute period of time.
GM-CSF (granulocyte macrophage colony stimulating factor) 0.1 ml given slowly i.v. Use tuberculin syringe.
2 hours later IL-6 (interleukin 6 and interleukin10)) given i.v plus natural killer cells and patient’s own macrophages i.v., and CD4+ and CD8+ derived from the patient.
2 hours later anti Notch 0.1 ml; anti-Hedgehog 0.1 ml; and 0.1 ml anti Wnt-Catenin to be given as three separate injections in the arms subcutaneously using a tuberculin syringe with a half inch #27 needle. This provides a selective blockade of growth factor signaling inhibitors for advanced cancer. These agents induce the inhibition of growth, invasiveness and apopotoic death of cancer cells by counteracting distinct mitotic cascades. Normal cells are not injured to the cytotoxic effects of these agents.
Specific anti-gene agents are administered depending on the nature of the cancer (details supplied upon request)
Anti-angiogenesis factors administered.
Specific monoclonal antibodies administered.
Intravenous dendritic cells are given with any form of cancer. (More on next page),

ALTERNATIVE METHOD:
The use of autologous stem cells from the patient would be substituted in Step #1. This would be followed by infusion of the patient’s own T lymphocyte NK cells that have been incubated with IL-2. The rest of steps #2 through 4 would remain the same.


		ADVANCED CANCER Candidates: Patients with advanced cancer that have had previous chemotherapy and/or radiation and/or surgery that has failed and the patient has had recurrence or metastasis. Age and severity of the current condition do not limit the availability of this treatment. Ideally we would request a detailed summary of the patient’s records including biopsy reports, most recent laboratory findings, x-ray results and list of all previous treatments; an immunological profile including T and B lymphocytes, NK cells, T cytotoxic cells and T regulatory (suppressor) cells. The attack is focused on residual cancer stem cells that have resisted chemotherapy or radiation effects. Patients undergoing treatment will receive the following approach: Infusion autologous stem cells and CD33+ and CD134+ cells i.v. over a ten minute period of time. GM-CSF (granulocyte macrophage colony stimulating factor) 0.1 ml given slowly i.v. Use tuberculin syringe. 2 hours later IL-6 (interleukin 6 and interleukin10)) given i.v plus natural killer cells and patient’s own macrophages i.v., and CD4+ and CD8+ derived from the patient. 2 hours later anti Notch 0.1 ml; anti-Hedgehog 0.1 ml; and 0.1 ml anti Wnt-Catenin to be given as three separate injections in the arms subcutaneously using a tuberculin syringe with a half inch #27 needle. This provides a selective blockade of growth factor signaling inhibitors for advanced cancer. These agents induce the inhibition of growth, invasiveness and apopotoic death of cancer cells by counteracting distinct mitotic cascades. Normal cells are not injured to the cytotoxic effects of these agents. Specific anti-gene agents are administered depending on the nature of the cancer (details supplied upon request) Anti-angiogenesis factors administered. Specific monoclonal antibodies administered. Intravenous dendritic cells are given with any form of cancer. (More on next page), ALTERNATIVE METHOD: The use of autologous stem cells from the patient would be substituted in Step #1. This would be followed by infusion of the patient’s own T lymphocyte NK cells that have been incubated with IL-2. The rest of steps #2 through 4 would remain the same. .